Metagenomi Files 8-K Report
Ticker: MGX · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1785279
| Field | Detail |
|---|---|
| Company | Metagenomi, Inc. (MGX) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
Metagenomi filed a routine 8-K, no major news.
AI Summary
On December 9, 2024, Metagenomi, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is based in Emeryville, California, and operates in the biological products sector.
Why It Matters
This 8-K filing indicates Metagenomi, Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without detailing any specific material events, suggesting no immediate new risks are disclosed.
Key Players & Entities
- Metagenomi, Inc. (company) — Registrant
- December 09, 2024 (date) — Date of earliest event reported
- Emeryville, California (location) — Principal Executive Offices
- 001-41949 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Metagenomi, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 9, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 09, 2024.
Where are Metagenomi, Inc.'s principal executive offices located?
Metagenomi, Inc.'s principal executive offices are located at 5959 Horton Street, 7th Floor, Emeryville, California, 94608.
What is Metagenomi, Inc.'s Commission File Number?
Metagenomi, Inc.'s Commission File Number is 001-41949.
What is the Standard Industrial Classification for Metagenomi, Inc.?
The Standard Industrial Classification for Metagenomi, Inc. is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-09 21:22:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MGX Nasdaq Glob
Filing Documents
- mgx-20241209.htm (8-K) — 40KB
- mgx-ex99_1.htm (EX-99.1) — 20KB
- img133734535_0.jpg (GRAPHIC) — 109KB
- 0000950170-24-134733.txt ( ) — 334KB
- mgx-20241209.xsd (EX-101.SCH) — 26KB
- mgx-20241209_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 9, 2024, Metagenomi, Inc. (the "Company") issued a press release announcing the Company presented updated preclinical nonhuman primate data for its hemophilia A program in an oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting and Exposition in San Diego. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein .
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Metagenomi, Inc. on December 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Metagenomi, Inc. Date: December 9, 2024 By: /s/ Brian C. Thomas Brian C. Thomas, Ph.D. Chief Executive Officer